safety by nature depictionsafety by nature depiction

Intralytix receives Safe Quality Food (SQF) certification

4 months ago

Columbia, Maryland, USA. – February 14, 2024 – Intralytix announced today that it has received the highly coveted Safe Quality Food (SQF) certification for food manufacturing. This comprehensive Hazard Analysis and Critical Control Points (HACCP)-based food safety and quality management certification sets Intralytix apart as the first and so far, the only bacteriophage company in history to attain such certification.

Hal Warso, Director of Quality Assurance of Intralytix, Inc.
Hal Warso, Director of Quality Assurance at Intralytix, commented: “SQF is an international food safety standard recognized by the Global food safety Initiative, which is approved as one of the benchmarked schemes for meeting very stringent requirements for food safety management systems worldwide. Intralytix receiving SQF certification is a testament to our dedication to producing safe and high-quality phage products for all our customers, and it further underscores the revolutionary impact that bacteriophage-based antimicrobials can have on ensuring a safer food supply chain.” Alexander Sulakvelidze, President and CEO of Intralytix, echoed the significance of this milestone, stating, "Our Company always has been on the forefront of everything bacteriophage technology-related, including acquiring and maintaining Kosher, Halal, and OMRI (organic) certifications for our phage products for food safety applications. We were the first phage company in the World to manufacture phage products in compliance with 21 CFR 117 cGMP standards. We have now added SQF certification to the list.” Dr. Sulakvelidze concluded: “This SQF certification is yet another milestone in Intralytix's commitment to ensuring the highest standards of our phage products and food safety and quality. It further solidifies the Company's position as a leader in the development and production of bacteriophage-based antimicrobials, providing innovative solutions to combat the growing global concerns of antibiotic resistance and foodborne illnesses."

Intralytix's bacteriophage-based antimicrobials offer a sustainable, environmentally friendly, and targeted approach for controlling harmful bacteria in food products, ensuring the safety and well-being of consumers in the United States. With SQF certification in hand, the company is poised to set new industry standards and continue its mission to provide innovative solutions to the global challenges of antibiotic resistance and foodborne illnesses.

About Intralytix, Inc.

Dr. Alexander "Sandro" Sulakvelidze, President & CEO of Intralytix.
Intralytix is a cutting-edge United States biotechnology company dedicated to developing and producing bacteriophage-based antimicrobials. With a commitment to innovation and excellence, Intralytix is using its core bacteriophage technology platform to improve human health through the development and commercialization of innovative bacteriophage-based products for food safety, veterinary applications, human therapeutics, oral care, cosmetic, and dietary supplements/probiotic applications. The Company currently has the largest in the World portfolio of FDA- and USDA-approved phage products on the market for food safety applications. These products ensure the safety of foods against major foodborne bacterial pathogens such as Listeria monocytogenes, Salmonella spp., Shigella spp., Campylobacter spp., and Shiga toxin producing Escherichia coli or STEC (including E. coli O157:H7 and all “big six” STEC). Intralytix is actively expanding its nutraceutical product portfolio and is also working on developing phage therapeutics to combat various drug-resistant bacterial pathogens. To that end, Intralytix is currently the sponsor of three Investigational New Drugs (INDs) for randomized, controlled clinical trials designed to assess the safety and efficacy of oral administration of (1) EcoActive™ targeting adherent invasive E. coli (AIEC) in patients with inactive Crohn's disease (NCT03808103); (2) ShigActive™ targeting Shigella in a human model of shigellosis (NCT05182749); and (3) VRELysin™ targeting vancomycin-resistant Enterococci (VRE) in healthy and VRE colonized subjects (NCT05715619). For more information, please visit or contact Dr. Alexander “Sandro” Sulakvelidze (410-625-2533,